Diabetes is chronic metabolic disorder which growing fast ground world. Dipeptidyl peptidase IV (DPP4) inhibitors are proven in the treatment of type 2 diabetes. DPP-4 is a target during controlling diabetes glycemic control. DPP-4 inhibitors have been shown to be generally well tolerated with a low risk of hypoglycemia and neutral weight gain and have anticipated longterm beneficial effects on β-cell function. A number of DPP-4 inhibitor develop rapidly for management of type-2 diabetes. This article review development of synthetic sulphonamide derivative as a DPP-4 inhibitor from 2004 to 2017 and provide SAR, biological activities against DPP-4 and selectivity over DPP-8/DPP-9.
Keywords: DPP4 inhibitors, Sulfonamide derivative, Type 2 diabetes.